

Study or Subgroup	SSRI		Placebo		Weight	Risk Ratio		Risk Ratio M-H, Random, 95% CI
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI	
29060/449 (A)	19	108	4	55	0.9%	2.42	[0.87, 6.76]	
29060/449 (B)	7	112	4	55	0.7%	0.86	[0.26, 2.81]	
29060/448 (A)	18	106	3	51	0.7%	2.89	[0.89, 9.35]	
29060/448 (B)	21	106	4	52	0.9%	2.58	[0.93, 7.12]	
29060/785 (A)	16	103	2	27	0.5%	2.10	[0.51, 8.57]	
29060/785 (B)	13	96	2	26	0.5%	1.76	[0.42, 7.31]	
29060/785 (C)	10	107	2	26	0.4%	1.21	[0.28, 5.21]	
29060/785 (D)	13	100	1	26	0.2%	3.38	[0.46, 24.67]	
Ball et al. (2014)	12	79	6	79	1.1%	2.00	[0.79, 5.06]	
Blumenthal et al. 2007	15	49	6	49	1.3%	2.50	[1.06, 5.91]	
Bose 2008	19	130	5	134	1.0%	3.92	[1.51, 10.18]	
Burke et al. (A) 2002	10	119	7	122	1.1%	1.46	[0.58, 3.72]	
Burke et al. (B) 2002	14	125	7	122	1.2%	1.95	[0.82, 4.67]	
Burke et al. (C) 2002	11	125	7	122	1.1%	1.53	[0.61, 3.83]	
Byerley et al. 1988	0	32	16	29	0.1%	0.03	[0.00, 0.44]	
Claghorn 1992a	6	36	3	35	0.5%	1.94	[0.53, 7.17]	
Claghorn et al. 1996	9	47	1	46	0.2%	8.81	[1.16, 66.77]	
Coleman et al. 1999	21	115	17	121	2.7%	1.30	[0.72, 2.34]	
Coleman et al. 2001	18	154	13	152	2.0%	1.37	[0.69, 2.69]	
Croft et al. 1999	31	118	13	119	2.6%	2.40	[1.33, 4.36]	
Davidson et al. 2002	42	111	22	116	4.7%	2.00	[1.28, 3.11]	
Dunlop et al (A)	19	105	2	20	0.5%	1.81	[0.46, 7.17]	
Dunlop et al (B)	17	104	1	19	0.2%	3.11	[0.44, 21.97]	
Dunlop et al (C)	14	107	1	19	0.2%	2.49	[0.35, 17.81]	
Edwards et al. 1993	1	21	0	20	0.1%	2.86	[0.12, 66.44]	
Fabre et al. 1987	4	72	0	12	0.1%	1.60	[0.09, 28.03]	
Fabre et al. 1995	60	278	8	91	1.9%	2.46	[1.22, 4.94]	
Fabre et al. 1996	7	46	5	44	0.8%	1.34	[0.46, 3.91]	
Fava et al. 2005	7	47	4	43	0.7%	1.60	[0.50, 5.09]	
Feighner et al. 1999	73	521	14	129	3.2%	1.29	[0.75, 2.21]	
Goldstein et al (2002)	10	33	7	70	1.2%	3.03	[1.27, 7.25]	
Griebel et al. 2012 a	7	84	1	75	0.2%	6.25	[0.79, 49.63]	
Griebel et al. 2012 b	6	80	5	77	0.7%	1.16	[0.37, 3.63]	
Higuchi et al. (A) 2011	7	161	4	86	0.6%	0.93	[0.29, 3.10]	
Higuchi et al. (B) 2011	7	83	4	86	0.7%	1.81	[0.55, 5.97]	
Kasper (A) 2005	3	173	5	90	0.5%	0.31	[0.08, 1.28]	
Kasper (B) 2005	8	164	4	90	0.7%	1.10	[0.34, 3.54]	
Learned et al. 2012	16	166	9	156	1.5%	1.67	[0.76, 3.67]	
Lepola et al. (A) 2003	10	155	2	77	0.4%	2.48	[0.56, 11.06]	
Lepola et al. (B) 2003	12	160	3	77	0.6%	1.93	[0.56, 6.82]	
LVM-MD-06	9	79	8	93	1.1%	1.32	[0.54, 3.27]	
MY-1043/BRL-029060/115 (A)	45	284	5	59	1.2%	1.87	[0.78, 4.51]	
MY-1043/BRL-029060/115 (B)	42	289	4	59	1.0%	2.14	[0.80, 5.75]	
MY-1045/BRL-029060/1 (PAR128) (A)	49	357	8	70	1.9%	1.20	[0.60, 2.42]	
MY-1045/BRL-029060/1 (PAR128) (B)	63	351	8	70	2.0%	1.57	[0.79, 3.13]	
NCT00668525 (A)	30	322	7	109	1.5%	1.45	[0.66, 3.21]	
NCT00668525 (B)	35	324	7	109	1.5%	1.68	[0.77, 3.68]	
NCT01020799	7	50	4	99	0.7%	3.46	[1.06, 11.28]	
NCT01473381	30	282	26	281	3.8%	1.15	[0.70, 1.89]	
Nemeroff et al. 2007	13	104	9	102	1.4%	1.42	[0.63, 3.17]	
Nierenberg et al. (2007)	33	274	11	137	2.2%	1.50	[0.78, 2.88]	
Norton et al. 1984	8	35	2	25	0.4%	2.86	[0.66, 12.33]	
Olie et al. 1997	6	129	3	129	0.5%	2.00	[0.51, 7.83]	
PAR 29060.07.001	4	13	1	12	0.2%	3.69	[0.48, 28.57]	
Peselow et al. 1989a	2	40	4	42	0.3%	0.53	[0.10, 2.71]	
Rapaport (A) 2008	19	164	11	89	1.9%	0.94	[0.47, 1.88]	
Rapaport (B) 2008	26	173	10	89	2.0%	1.34	[0.68, 2.65]	
Ratti et al. 2011	11	120	5	120	0.9%	2.20	[0.79, 6.14]	
Reimherr et al. 1990	35	149	15	150	3.0%	2.35	[1.34, 4.12]	
Rickels et al. 1992	15	55	4	56	0.9%	3.82	[1.35, 10.78]	
Roose 2004	13	87	6	90	1.1%	2.24	[0.89, 5.63]	
Rudolph et al. 1999	19	103	9	98	1.7%	2.01	[0.96, 4.22]	
Schatzberg 2006	13	100	14	96	1.9%	0.89	[0.44, 1.80]	
Schneider 2003	68	371	25	376	4.9%	2.76	[1.78, 4.26]	
SCT-MD 02 (A) 2002	12	125	6	64	1.1%	1.02	[0.40, 2.60]	
SCT-MD 02 (B) 2002	18	123	5	63	1.1%	1.84	[0.72, 4.74]	
SCT-MD-13	19	132	5	135	1.0%	3.89	[1.49, 10.10]	
SCT-MD-26	15	154	7	155	1.2%	2.16	[0.90, 5.14]	
SCT-MD-27 (A)	10	136	4	67	0.7%	1.23	[0.40, 3.78]	
SCT-MD-27 (B)	19	138	5	68	1.1%	1.87	[0.73, 4.80]	
SCT-MD-35	6	138	8	135	0.9%	0.73	[0.26, 2.06]	
Smith et al. 1992	2	39	4	38	0.3%	0.49	[0.09, 2.51]	
Tollefson et al. 1995	48	335	30	336	5.1%	1.60	[1.04, 2.47]	
Walczak et al. 1996	51	400	24	200	4.5%	1.06	[0.67, 1.67]	
Wang et al 2014	19	156	11	155	1.9%	1.72	[0.85, 3.49]	
WELL.AK130926	15	149	12	137	1.8%	1.15	[0.56, 2.37]	
WELL.AK130927	16	138	10	141	1.6%	1.63	[0.77, 3.48]	

Total (95% CI) 11056 7099 100.0% 1.66 [1.51, 1.83]
 Total events 1458 561
 Heterogeneity: Tau² = 0.00; Chi² = 75.02, df = 76 (P = 0.51); I² = 0%
 Test for overall effect: Z = 10.28 (P < 0.00001)

